Invesco Pharmaceuticals ETF
PJP

$87

1.21%

Market Cap: $290M

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

17.91% more ownership

Funds ownership: 4.96% [Q1] → 22.88% (+17.91%) [Q2]

5% less funds holding

Funds holding: 93 [Q1] → 88 (-5) [Q2]

13% less capital invested

Capital invested by funds: $72M [Q1] → $62.9M (-$9.15M) [Q2]

32% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 28

36% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 14

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PJP.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

The Invesco Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

PJP: A Dynamic Pharma Fund

Bullish on pharmaceuticals and health care due to relative momentum and preference for "need" sectors over cyclical ones. The Invesco Pharmaceuticals ETF provides exposure to select pharmaceutical stocks with specific criteria for selection and a dynamic approach. The fund holds 24 stocks, primarily in pharmaceuticals, biotech, and healthcare equipment, with heavyweights like AbbVie, Regeneron, Eli Lilly, and Abbott Laboratories.

PJP: A Dynamic Pharma Fund

Zacks Investment Research

Pharma ETFs in Focus Post Solid Q2 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Zacks Investment Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on 06/23/2005.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund launched on 06/23/2005.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Zacks Investment Research

A Look at Pharma ETFs Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs Post Q1 Earnings

Zacks Investment Research

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

A smart beta exchange traded fund, the Invesco Pharmaceuticals ETF (PJP) debuted on 06/23/2005, and offers broad exposure to the Health Care ETFs category of the market.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

See News Rankings